Pacira BioSciences, Inc.
Summary
This filing is NOT a Rule 506(b) or 506(c) Form D for capital raising. It is a Form DEFA14A — a notice regarding a definitive proxy material filing by Pacira BioSciences, Inc. (ticker: PCRX), a publicly traded company. No new capital was raised via this filing; the $65.0M figure appears to be a data entry error and does not represent proceeds from a private placement.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Full Analysis
Executive Summary
This filing is NOT a Rule 506(b) or 506(c) Form D for capital raising. It is a Form DEFA14A — a notice regarding a definitive proxy material filing by Pacira BioSciences, Inc. (ticker: PCRX), a publicly traded company. No new capital was raised via this filing; the $65.0M figure appears to be a data entry error and does not represent proceeds from a private placement.
Investor Edge
Ignore this filing for private placement intelligence. Sophisticated investors should check Pacira's definitive proxy statement filed under the same accession number for any shareholder proposals or board changes.
Sector capital positioning
No genuine private capital signal; the company is a public biopharmaceutical firm focused on non-opioid pain management, not a 'Technology Venture' as mislabeled. This filing does not reflect sector capital flows.
Convergence Signals
None. Filing is an SEC-required proxy disclosure unrelated to a capital raise, patents, contracts, or legislation.
Key Takeaways
- This is a proxy filing, not a private placement; $65.0M is not capital raised.
- Data incorrectly classifies a public biopharma as 'Technology Venture' and 'Unknown' state.
- No actionable intelligence for private capital investors from this filing.
Risk Indicators & Flags
MISCLASSIFIED FILING TYPE: DEFA14A is not a Form D. Incorrect industry label and capital amount suggest a data scraping or parsing error. No genuine regulatory or offering risk.
Verification & References
Verify the filer: SEC EDGAR search for '0001396814' shows Pacira BioSciences as a public company (CRX:PCRX). Accession 000162828026039589 is for a DEFA14A, not a Form D. The industry 'Technology Venture' is inconsistent with a biopharma company. The $65.0M 'Capital Raised' field is likely a data mapping error.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Matthias Therapeutics, LLC
Uniform Bio Inc.
Dare Bioscience, Inc.
Anika Therapeutics, Inc.
DEF 14A - Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc.
Strategy Inc
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Declaring a National Emergency to Secure the United States Bulk-Power System
This executive order declares a national emergency to restrict foreign-produced bulk-power system electric equipment that poses national security risks, prohibiting new transactions involving equipment from covered foreign entities and allowing the Secretary of Energy to impose conditions on existing equipment. It directs the Secretary of Energy, in coordination with multiple agencies, to identify, mitigate, and potentially replace risky equipment, and establishes a pre-qualification list for approved vendors.
The National Space Transportation Policy
This memorandum directs multiple agencies to expand and modernize U.S. space launch and reentry infrastructure to support over 1,000 launches annually by 2030, expedite permitting and environmental reviews, develop new federal reentry sites, and strengthen the space transportation industrial base. It mandates range scheduling transparency, spectrum reliability, and workforce development, with specific reports and plans due within 90 to 240 days.
Adjusting Imports of Unmanned Aircraft Systems and Unmanned Aircraft Systems Components into the United States
This proclamation imposes a 100% ad valorem tariff on imports of unmanned aircraft systems (UAS) over 25 kg, those with thermal imagers, docking stations, and certain components, and a 25% tariff on UAS under 25 kg and other components, citing national security under Section 232 of the Trade Expansion Act. It also authorizes the Department of Commerce to establish an onshoring program offering preferential tariff treatment for companies that build new U.S. manufacturing facilities for UAS and components.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →